Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

This study is testing a new drug called JK07 in people with heart failure who also have pulmonary hypertension — specifically a type where both the veins going into the lungs AND the lung arteries themselves are under excess pressure (combined pre- and post-capillary pulmonary hypertension). **You may be eligible if...** - You have heart failure with Class II or III symptoms (some or moderate limitations on activity) - You have either heart failure with reduced ejection fraction (HFrEF, pumping function ≤40%) or preserved ejection fraction (HFpEF, 40-70%) - A right heart catheterization has confirmed elevated pressures in both the lung veins and lung arteries **You may NOT be eligible if...** - Your pulmonary hypertension belongs to a different WHO category (Group 1, 3, 4, or 5 — meaning it's not caused by left heart disease) - You have a known lung condition or have had part of your lung removed - Your BMI is above 45 - You have a contraindication to having a right heart catheter left in place for about 6 hours Talk to your doctor to see if this trial is right for you.